Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Surgical Debulking Prior to PRRT in GEP-NETs
NCT06016855Phase 4Recruiting
- Sponsor
- Vanderbilt-Ingram Cancer Center
- Start
- May 2024
- Primary completion
- May 2027
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of lutetium Lu 177 dotatate in gastroenteropancreatic neuroendocrine tumor (GEP-NET), sponsored by Vanderbilt-Ingram Cancer Center. Primary endpoints: Somatostatin receptor standardized uptake values up to 2 years, Progression-free survival up to 2 years and 4 more. Started May 2024; status: recruiting.
02
Drugs
lutetium Lu 177 dotatate
03
Conditions
gastroenteropancreatic neuroendocrine tumor (GEP-NET)
Beyond the preview
Go deeper on NCT06016855.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06016855.